Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NF1 Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03989115
What this trial is testing

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Who this might be right for
Solid Tumor
Revolution Medicines, Inc. 113
Testing effectiveness (Phase 2)Study completedNCT02352844
What this trial is testing

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Who this might be right for
Solid MalignancySolid Tumor
Washington University School of Medicine 12
Testing effectiveness (Phase 2)Ended earlyNCT05554354
What this trial is testing

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Study completedNCT02101736
What this trial is testing

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Who this might be right for
NF1NeurofibromatosisPlexiform Neurofibromas
University of Alabama at Birmingham 45
Large-scale testing (Phase 3)Ended earlyNCT05130866
What this trial is testing

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Who this might be right for
Neurofibromatosis Type 2
Recursion Pharmaceuticals Inc. 25
Post-approval studies (Phase 4)Active Not RecruitingNCT03975829
What this trial is testing

Pediatric Long-Term Follow-up and Rollover Study

Who this might be right for
Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytoma+20 more
Novartis Pharmaceuticals 163
Testing effectiveness (Phase 2)Looking for participantsNCT07237100
What this trial is testing

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Who this might be right for
Advanced Unresectable MelanomaMetastatic Melanoma
Kevin Kim, MD 10
Early research (Phase 1)Ended earlyNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 29